Department of Dermatology-Allergology, Tenon Hospital, Paris, France.
Dermatology. 2009;219(3):263-7. doi: 10.1159/000235582. Epub 2009 Aug 13.
Anti-tumor-necrosis-factor-alpha agents are limited by their side effects. Eczema is one of the most frequent adverse reactions affecting quality of life.
To assess potential predictive risk factors for eczema in patients receiving infliximab.
We conducted a prospective cohort study including patients treated with infliximab for a variety of disorders with the exception of cutaneous psoriasis. Clinical features were compared among patients with and without eczema under therapy.
92 consecutive patients were included; 15 developed eczema after the initiation of infliximab. In univariate analyses, a personal history of atopic symptoms was the only predictive factor for the occurrence of eczema (odds ratio = 3.6). Sex, age, principal diagnosis, dose and duration of infliximab and concomitant use of other immunosuppressors had no influence on the occurrence of eczema.
A personal history of atopic symptoms is predictive of eczema under infliximab. Specific information should be provided to atopic patients starting such a treatment.
抗肿瘤坏死因子-α 制剂受到其副作用的限制。湿疹是影响生活质量的最常见不良反应之一。
评估接受英夫利昔单抗治疗的患者发生湿疹的潜在预测风险因素。
我们进行了一项前瞻性队列研究，纳入了除皮肤银屑病以外的多种疾病接受英夫利昔单抗治疗的患者。在治疗期间比较了有和无湿疹的患者的临床特征。
共纳入 92 例连续患者，其中 15 例在开始使用英夫利昔单抗后出现湿疹。单因素分析中，特应性症状的个人史是湿疹发生的唯一预测因素（比值比=3.6）。性别、年龄、主要诊断、英夫利昔单抗的剂量和疗程以及同时使用其他免疫抑制剂对湿疹的发生没有影响。
特应性症状的个人史是英夫利昔单抗治疗下发生湿疹的预测因素。开始这种治疗时应向特应性患者提供具体信息。
